TABLE 4.

Logistic Regression Model for Predictors of Gain of VL Suppression Among Previously Unsuppressed CALHIV After Shifting to DTG Using SDS With DTG

Characteristic (N)	OR (95% CI)
Pre-DTG ART regimen
TLE → TLD (n = 590)*	1
TDF-3TC-PI →TLD (n = 214)	1.36 (0.55–3.36)
ABC-3TC-NNRTI → ABC-3TC-DTG (n = 560)	0.66 (0.26–1.66)
ABC-3TC-PI → ABC-3TC-DTG (n = 370)	1.05 (0.42–2.61)
Country/Site
Botswana (n = 90)*	1
Eswatini (n = 246)	Indet.†
Lesotho (n = 206)	0.16 (0.03–0.86)
Malawi (n = 340)	0.38 (0.13–1.12)
Tanzania (n = 248)	1.57 (0.58–4.23)
Uganda (n = 604)	0.49 (0.19–1.29)
Age category
0–4.99 years (n = 4)	Indet.†
5–9.99 years (n = 356)	0.75 (0.36–1.54)
10–14.99 years (n = 571) *	1 (REF)
15–19.99 years (n = 803)	0.60 (0.28–1.27)
Sex
Female (n = 1021)	0.99 (0.58–1.68)
Male (n = 713)*	1

^*Reference Category within variable.

^†Indeterminant due to small sample size and/or outcome event rate not allowing for enough power to report an OR.

ART indicates antiretroviral therapy; CALHIV, children and adolescents living with HIV; CI, confidence interval; DTG, dolutegravir; N/A, not applicable; NNRTI, nonnucleoside reverse transcriptase inhibitor; OR, odds ratio; PI, protease inhibitor; SDS, single drug substitution; VL, viral load.